pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
346
stories
Aug 11, 26
AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinois
endpoints
Aug 10, 26
Bristol Myers details new $2.3B manufacturing campus in Houston
endpoints
Aug 10, 26
BMS picks Texas for new $2.3B manufacturing campus
biospace
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Aug 10, 26
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
Aug 10, 26
Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes
raps
Aug 7, 26
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Aug 6, 26
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
Aug 5, 26
Merger talks between AstraZeneca, Bristol Myers are off — report
endpoints
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 5, 26
5 NextGen winners who went public this year (and which ones are hiring)
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 4, 26
Icon inks Anthropic partnership to deploy Claude into clinical trials
fiercebiotech
Aug 4, 26
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
Aug 3, 26
Biopharma industry questions potential AstraZeneca, Bristol Myers merger
endpoints
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
Aug 3, 26
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
stat
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
← prev
page 8 of 12
next →